8-K: INVO Bioscience Faces Nasdaq Delisting Notice and Restates Financials Due to Accounting Error

INVO Bioscience received a delisting notice from Nasdaq for failing to maintain a minimum share price and will restate past financial statements due to an accounting error.

Summary

• INVO Bioscience has received a notification from Nasdaq stating that the company is not in compliance with the minimum bid price requirement of $1.00 per share.
• The company's stock price has been below $1.00 for the last 34 consecutive business days.
• INVO has been granted an initial period until May 17, 2025, to regain compliance.
• The company can regain compliance if its stock price closes at or above $1.00 for at least 10 consecutive business days.
• If compliance is not achieved by May 17, 2025, a second 180-day period may be granted if certain conditions are met, including a potential reverse stock split.
• The company is also restating its previously issued financial statements due to an error in calculating the value of right-of-use assets and lease liabilities.
• The error involved using federal rates instead of the company's incremental borrowing rates for discounting lease liabilities.
• The restatement will impact the company's assets and liabilities but will not affect revenue, results of operations, earnings per share, or net equity.
• The company's management and audit committee have discussed these matters with their independent accounting firm.

Sentiment

Score: 3

Explanation: The document contains negative news regarding a delisting notice and financial restatement, indicating significant challenges for the company.

Positives

• The delisting notice has no immediate effect, and the company's stock will continue to trade on Nasdaq.
• INVO has been given a period of 180 days to regain compliance with the minimum bid price requirement.
• The accounting error did not impact the company's revenue, results of operations, earnings per share, or net equity.
• The company is taking steps to correct the accounting error and restate its financial statements.

Negatives

• The company's stock price has fallen below the minimum bid price requirement of $1.00 per share.
• The company is at risk of being delisted from Nasdaq if it does not regain compliance.
• The company must restate its financial statements due to an accounting error.
• There is no guarantee that the company will regain compliance with Nasdaq listing requirements.

Risks

• The company faces the risk of delisting from Nasdaq if it cannot raise its stock price above $1.00 by May 17, 2025, or within any subsequent extension period.
• The restatement of financial statements could raise concerns among investors.
• The company may need to consider a reverse stock split to regain compliance, which could negatively impact shareholders.
• There is no assurance that the company will maintain compliance with other Nasdaq listing requirements.

Future Outlook

The company will monitor its stock price and consider options to regain compliance with Nasdaq listing rules, including a potential reverse stock split. The company intends to file amended reports with restated financial statements.

Management Comments

• The company will continue to monitor the closing bid price of its common stock and will consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
• The company's management and the Audit Committee have discussed the matters described herein with M&K CPAs, LLC, the company's independent registered public accounting firm.

Industry Context

Delisting notices are not uncommon for companies that fail to maintain minimum share prices, especially in volatile markets. Restatements due to accounting errors can also occur, highlighting the importance of robust internal controls and accurate financial reporting.

Comparison to Industry Standards

• Many companies listed on Nasdaq face similar challenges with maintaining minimum bid prices, especially smaller cap companies.
• Restatements of financial statements are not uncommon, but the impact varies depending on the nature and magnitude of the error.
• Companies like Cassava Sciences and Ocugen have also faced scrutiny and restatements, highlighting the importance of accurate financial reporting in the biotech sector.
• The use of incorrect discount rates for lease liabilities is a common error, and companies like Bed Bath & Beyond have also had to restate financials for similar reasons.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the delisting notice and financial restatement.
• Employees may be concerned about the company's future prospects.
• Creditors may be more cautious about extending credit to the company.

Next Steps

• The company will monitor its stock price to regain compliance with Nasdaq listing rules.
• The company will file amended reports with restated financial statements.
• The company may consider a reverse stock split to regain compliance.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, restatement, financial statements, accounting error, lease liabilities, reverse stock split, INVO Bioscience